Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies
Campbell, R.K.; Cobble, M.E.; Reid, T.S.; Shomali, M.E.
Journal of Family Practice 59(9 Suppl 1: S20-S27
2010
ISSN/ISBN: 1533-7294 PMID: 20824236 Document Number: 645824
The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.